JP2006513139A5 - - Google Patents

Download PDF

Info

Publication number
JP2006513139A5
JP2006513139A5 JP2004519544A JP2004519544A JP2006513139A5 JP 2006513139 A5 JP2006513139 A5 JP 2006513139A5 JP 2004519544 A JP2004519544 A JP 2004519544A JP 2004519544 A JP2004519544 A JP 2004519544A JP 2006513139 A5 JP2006513139 A5 JP 2006513139A5
Authority
JP
Japan
Prior art keywords
antibody
aerosol
aerosol formulation
formulation according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2004519544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006513139A (ja
Filing date
Publication date
Priority claimed from PCT/US2002/021335 external-priority patent/WO2003077834A2/en
Application filed filed Critical
Priority claimed from PCT/US2003/014428 external-priority patent/WO2004004798A2/en
Publication of JP2006513139A publication Critical patent/JP2006513139A/ja
Publication of JP2006513139A5 publication Critical patent/JP2006513139A5/ja
Ceased legal-status Critical Current

Links

JP2004519544A 2002-07-03 2003-05-09 治療薬の全身性送達のための中央部気道投与 Ceased JP2006513139A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2002/021335 WO2003077834A2 (en) 2002-03-15 2002-07-03 Central airway administration for systemic delivery of therapeutics
PCT/US2003/014428 WO2004004798A2 (en) 2002-07-03 2003-05-09 Central airway administration for systemic delivery of therapeutics

Publications (2)

Publication Number Publication Date
JP2006513139A JP2006513139A (ja) 2006-04-20
JP2006513139A5 true JP2006513139A5 (https=) 2006-09-14

Family

ID=30113575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004519544A Ceased JP2006513139A (ja) 2002-07-03 2003-05-09 治療薬の全身性送達のための中央部気道投与

Country Status (5)

Country Link
EP (1) EP1539246A4 (https=)
JP (1) JP2006513139A (https=)
AU (1) AU2003232081B2 (https=)
CA (1) CA2491129A1 (https=)
WO (1) WO2004004798A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
BRPI0507174A (pt) 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
BRPI0814465B1 (pt) 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
EP2203180B1 (en) * 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
BRPI0918670B8 (pt) 2008-09-17 2021-05-25 Xencor Inc anticorpo
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
CN102492039B (zh) * 2011-11-21 2015-03-11 无锡天演生物技术有限公司 全人源抗人her2单抗
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP3125942B8 (en) 2014-04-03 2021-12-01 CSL Behring AG Nebulization of immunoglobulin
EP3194449A1 (en) 2014-07-24 2017-07-26 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
MX392636B (es) 2014-10-31 2025-03-24 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
AU2016355563A1 (en) * 2015-11-16 2018-06-21 The Trustees Of The University Of Pennsylvania Targeted delivery of therapeutic proteins bioencapsulated in plant cells to cell types of interest for the treatment of disease
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
US12129302B2 (en) 2021-08-25 2024-10-29 Ibio, Inc. Anti-CD-25 antibody

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
EP1658772A3 (en) * 1995-01-17 2007-01-17 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
AU2002219944B2 (en) * 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2001238079A1 (en) * 2000-02-09 2001-08-20 Med Immune, Inc. Antibody gene therapy with adeno-associated viral vectors
US7282219B2 (en) * 2000-03-31 2007-10-16 Kirin Beer Kabushiki Kaisha Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
SE0102067D0 (sv) * 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
JP2005526769A (ja) * 2002-03-15 2005-09-08 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療剤を全身搬送するための中央気道投与

Similar Documents

Publication Publication Date Title
JP2006513139A5 (https=)
Mirick et al. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words
US20230220102A1 (en) Cd25 antibodies
CN113544148B (zh) 中和乙型肝炎病毒的抗体和其用途
JP2020039360A5 (https=)
JP2005516044A5 (https=)
HRP20160632T1 (hr) Vezivne molekule specifične za rsv i sredstva za njihovu proizvodnju
CN102046654A (zh) 针对甲型流感病毒h5n1株系的抗体
JP2018512170A5 (https=)
WO2006050166A3 (en) Methods of preventing and treating rsv infections and related conditions
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use
HRP20160485T1 (hr) Anti-mezotelinska protutijela i njihova uporaba
HRP20150641T1 (hr) Anti -cd38 humana antitijela i njihove uporabe
WO2005090405A1 (ja) インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
CN101679513A (zh) 用于治疗呼吸道合胞病毒感染的重组抗体
JP2009509538A5 (https=)
RU2017115670A (ru) Лечение инфекции рсв
JP2008513354A5 (https=)
JP2019523651A5 (https=)
JP2011006464A (ja) 喘息の治療における抗−ＴＮＦα抗体
JP2020533965A5 (https=)
JP2017524359A (ja) Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
JP2024540148A5 (https=)
CN102292351A (zh) 结合il-13的配体
JP2013519690A5 (https=)